Illuminating Acromegaly: Lab Data Can Change HCP Engagement

Acromegaly, a rare hormonal disorder caused by excess growth hormone (GH) production, often goes undiagnosed for years. This delay can lead to serious health complications. Early diagnosis and treatment are crucial for improving patient outcomes. This is where the power of lab data comes into play.

Acromegaly primarily affects middle-aged adults, causing bones in the hands, feet, and face to increase in size. While a pituitary tumor is the most common cause, tumors in other parts of the body can also contribute. Diagnosing acromegaly can be challenging due to its gradual onset and the non-specific nature of its symptoms. The gold standard for diagnosis involves measuring serum Insulin-like Growth Factor 1 (IGF-1) levels, followed by an oral glucose tolerance test (OGTT) in some cases.

The Diagnostic Challenge: Because acromegaly is uncommon and its symptoms develop slowly, diagnosis is often delayed. This delay can have significant consequences for patients. Traditional methods of identifying HCPs treating acromegaly, such as claims data, often lag behind real-time patient activity. This is where Prognos Health offers a crucial advantage.

Prognos Health's Innovative Solution: For over 10 years, Prognos has partnered with leading pharmaceutical and biotech companies to address the diagnostic challenges of acromegaly. Our expertise in lab data analysis provides a unique and powerful solution for HCP identification and patient journey insights.

How Prognos Helps:

• Early HCP Identification: Our lab-based alerts identify HCPs managing patients of interest before they appear in claims data, enabling faster engagement and improved patient care.
• Undiagnosed Patient Identification: Prognos data helps uncover undiagnosed patients, allowing for timely intervention and treatment.
• New HCP Discovery: We identify HCPs treating acromegaly who may not be visible through claims data alone, expanding reach and market potential.

Real-World Results: A leading manufacturer of acromegaly treatments has partnered with Prognos for over a decade. By leveraging our weekly HCP alerts and patient profiles (based on IGF-1 scores, diagnosis, and demographics), they've reported a 6x increase in sales force effectiveness. This long-standing partnership demonstrates the value and impact of Prognos's data-driven solutions.

Partner with Prognos: If you're a pharmaceutical or biotech company seeking to improve HCP targeting, accelerate patient identification, and enhance patient journeys in acromegaly, contact Prognos Health today. Let us help you unlock the power of lab data to make a difference in the lives of patients.